Boston Scientific (BSX) 10-K Summary — Year Ended Dec 31, 2023
Boston Scientific develops and markets medical devices. The company reported revenue growth and increased profitability for the latest annual period.
Key takeaway
Year ended Dec 31, 2023 · FY2025 10-K
Boston Scientific develops and markets medical devices. The company reported revenue growth and increased profitability for the latest annual period.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$14.2B
Revenue reported for the fiscal year.
Operating income
$2.3B
Income from operations reported for the year.
Net income
$1.6B
Net income reported for the year.
Operating cash flow
$2.5B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $11.9B | n/a |
| Dec 31, 2022 | $12.7B | +6.7% |
| Dec 31, 2023 | $14.2B | +12.3% |
Business overview
Boston Scientific is a medical device manufacturer focused on interventional cardiology, rhythm management, endoscopy, urology, and neuromodulation. The company's products are used to diagnose or treat a range of medical conditions. Its operations are subject to regulatory oversight and competitive pressures.
Financial performance
The company's revenue increased compared to the prior year. Operating income and net income also rose. Cash flow from operations remained strong for the period.
Material risks
The company faces litigation risks, including ongoing and potential claims related to product liability and patents. Additional losses from litigation could materially affect operating results, cash flows, or compliance with credit agreement covenants. Restructuring activities also present execution and cost risks.
Liquidity and capital
The company has used cash and restructuring reserves to fund restructuring plans. Litigation-related net credits or charges have impacted reported cash flows and financial results.
What to watch
Monitor the outcome and potential costs of ongoing litigation, particularly claims related to transvaginal surgical mesh products.